Search
Neuralink is set to embark on a clinical study in the United Kingdom, aiming to evaluate the efficacy of its brain-machine interface chips in enabling severely paralyzed patients to control digital and physical tools through mere thoughts. Collaborating with University College London Hospitals NHS Foundation Trust and Newcastle Hospitals, the company will recruit patients suffering from paralysis due to spinal cord injuries or Amyotrophic Lateral Sclerosis (ALS) for this groundbreaking research. Currently, five patients are already utilizing this revolutionary device.
Prior to this, Neuralink secured $650 million in funding and commenced human trials in 2024, following the resolution of safety concerns raised by the US Food and Drug Administration. The company now boasts an estimated valuation of approximately $9 billion.
-
C114 Communication Network -
Communication Home
